Laura M. Bruzek

1.4k total citations
15 papers, 1.2k citations indexed

About

Laura M. Bruzek is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Laura M. Bruzek has authored 15 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Laura M. Bruzek's work include Cancer Treatment and Pharmacology (8 papers), Cancer-related Molecular Pathways (6 papers) and Advanced Breast Cancer Therapies (3 papers). Laura M. Bruzek is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Cancer-related Molecular Pathways (6 papers) and Advanced Breast Cancer Therapies (3 papers). Laura M. Bruzek collaborates with scholars based in United States, Ukraine and Israel. Laura M. Bruzek's co-authors include Alex A. Adjei, Scott H. Kaufmann, Lorelei J. Hanson, Charles Erlichman, Xue Meng, Chunrong Yu, Christopher A. Carter, Gregory J. Gores, Joel M. Reid and James R. Wright and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Oncogene.

In The Last Decade

Laura M. Bruzek

15 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Laura M. Bruzek United States 11 827 530 236 172 163 15 1.2k
Laure A Moutouh-de Parseval United States 6 922 1.1× 790 1.5× 165 0.7× 136 0.8× 140 0.9× 7 1.3k
Jay Gibbons United States 11 1.1k 1.3× 358 0.7× 193 0.8× 345 2.0× 148 0.9× 14 1.5k
Ivy Fearen United States 9 722 0.9× 288 0.5× 201 0.9× 116 0.7× 133 0.8× 11 926
G. Cropp United States 17 650 0.8× 518 1.0× 193 0.8× 158 0.9× 48 0.3× 41 1.1k
Andrew Dorr United States 16 737 0.9× 356 0.7× 110 0.5× 147 0.9× 86 0.5× 37 1.0k
Susan Korenchuk United States 13 896 1.1× 348 0.7× 165 0.7× 462 2.7× 112 0.7× 18 1.4k
Zainab Jagani United States 14 1.5k 1.8× 544 1.0× 161 0.7× 111 0.6× 362 2.2× 15 1.8k
Masao Iwata Japan 11 976 1.2× 294 0.6× 78 0.3× 209 1.2× 133 0.8× 13 1.6k
Richard Woessner United States 20 1.2k 1.5× 738 1.4× 183 0.8× 91 0.5× 129 0.8× 45 1.6k
Lauren M. Thorpe United States 5 862 1.0× 341 0.6× 79 0.3× 196 1.1× 141 0.9× 7 1.2k

Countries citing papers authored by Laura M. Bruzek

Since Specialization
Citations

This map shows the geographic impact of Laura M. Bruzek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura M. Bruzek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura M. Bruzek more than expected).

Fields of papers citing papers by Laura M. Bruzek

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura M. Bruzek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura M. Bruzek. The network helps show where Laura M. Bruzek may publish in the future.

Co-authorship network of co-authors of Laura M. Bruzek

This figure shows the co-authorship network connecting the top 25 collaborators of Laura M. Bruzek. A scholar is included among the top collaborators of Laura M. Bruzek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura M. Bruzek. Laura M. Bruzek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Cynthia, X., Sumithra J. Mandrekar, Steven R. Alberts, et al.. (2006). A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade™), in combination with paclitaxel and carboplatin in patients with advanced malignancies. Cancer Chemotherapy and Pharmacology. 59(2). 207–215. 35 indexed citations
2.
Lancet, Jeffrey E., Ivana Gojo, Jason Gotlib, et al.. (2006). A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood. 109(4). 1387–1394. 129 indexed citations
3.
Yu, Chunrong, Laura M. Bruzek, Xue Meng, et al.. (2005). The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene. 24(46). 6861–6869. 228 indexed citations
4.
5.
Dy, Grace K., James P. Thomas, George Wilding, et al.. (2005). A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer. Clinical Cancer Research. 11(9). 3410–3416. 58 indexed citations
6.
Yu, Chunrong, Laura M. Bruzek, Scott H. Kaufmann, Christopher Carter, & Alex A. Adjei. (2005). The Raf kinase Inhibitor BAY 43-9006 accelerates Mcl-1 degradation and regulates pro-apoptotic function. 65. 1448–1448. 4 indexed citations
7.
Dy, Grace K., Laura M. Bruzek, Gary A. Croghan, et al.. (2005). A Phase I Trial of the Novel Farnesyl Protein Transferase Inhibitor, BMS-214662, in Combination with Paclitaxel and Carboplatin in Patients with Advanced Cancer. Clinical Cancer Research. 11(5). 1877–1883. 23 indexed citations
8.
LoRusso, Patricia, Alex A. Adjei, Mary Varterasian, et al.. (2005). Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies. Journal of Clinical Oncology. 23(23). 5281–5293. 316 indexed citations
9.
Dy, Grace K., Laura M. Bruzek, Gary A. Croghan, et al.. (2004). A phase I trial of the farnesyltransferase (FT) inhibitor, BMS-214662 (B) in combination with paclitaxel (P) and carboplatin (C) in patients with advanced cancer. Journal of Clinical Oncology. 22(14_suppl). 3066–3066. 1 indexed citations
10.
Dy, Grace K., Laura M. Bruzek, Gary A. Croghan, et al.. (2004). A phase I trial of the farnesyltransferase (FT) inhibitor, BMS-214662 (B) in combination with paclitaxel (P) and carboplatin (C) in patients with advanced cancer. Journal of Clinical Oncology. 22(14_suppl). 3066–3066. 1 indexed citations
11.
Adjei, Alex A., Gary A. Croghan, Charles Erlichman, et al.. (2003). A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.. PubMed. 9(7). 2520–6. 40 indexed citations
12.
Chandra, Joya, Jennifer S. Hackbarth, Son B. Le, et al.. (2003). Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells. Blood. 102(13). 4512–4519. 58 indexed citations
13.
Adjei, Alex A., Ann M. Mauer, Laura M. Bruzek, et al.. (2003). Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 21(9). 1760–1766. 168 indexed citations
14.
Adjei, Alex A., J. Nathan Davis, Laura M. Bruzek, Charles Erlichman, & Scott H. Kaufmann. (2001). Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines.. PubMed. 7(5). 1438–45. 87 indexed citations
15.
Adjei, Alex A., Laura M. Bruzek, Charles Erlichman, et al.. (2001). Combination studies with the farnesyltransferase inhibitor R115777 and chemotherapy agents. European Journal of Cancer. 37. S216–S216. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laure A Moutouh-de Parseval Breakdown of academic impact, for papers by Jay Gibbons Breakdown of academic impact, for papers by Ivy Fearen Breakdown of academic impact, for papers by G. Cropp Breakdown of academic impact, for papers by Andrew Dorr Breakdown of academic impact, for papers by Susan Korenchuk Breakdown of academic impact, for papers by Zainab Jagani Breakdown of academic impact, for papers by Masao Iwata Breakdown of academic impact, for papers by Richard Woessner Breakdown of academic impact, for papers by Lauren M. Thorpe
Rankless by CCL
2026